A novel peptide, PLAEIDGIELTY, for the targeting of α9β1-integrins
Schneider H, Harbottle RP, Yokosaki Y, Kunde J, Sheppard D, Coutelle C (1998)
Publication Type: Journal article, Original article
Publication year: 1998
Journal
Book Volume: 429
Pages Range: 269-273
Journal Issue: 3
DOI: 10.1016/S0014-5793(98)00612-7
Abstract
Targeting gene therapy vectors to abundant receptors on airway epithelia may allow a significant enhancement of gene delivery and thereby be of particular importance for the gene therapy of cystic fibrosis. α9β1- Integrins are highly expressed throughout the human airway epithelia in vivo, irrespective of any particular clinical status. Aiming to improve the targeting of our non-viral integrin-mediated gene transfer systems to airway epithelia, we searched for a short tenascin C-derived peptide which would bind to these integrins. By utilizing recombinant bacteriophages that display overlapping regions of the third fibronectin type III repeat of tenascin C (TNfn3), we were able to localize its α9β1-integrin binding site to the B-C loop of TNfn3. A synthetic Pro-Leu-Ala-Glu-Ile-Asp-Gly-Ile-Glu-Leu-Thr- Tyr peptide (PLAEIDGIELTY) was shown to displace αa9β1-integrin- expressing cells completely from binding to TNfn3. This peptide, therefore, may prove useful both for the examination of the functional importance of α9β1-integrins in vivo and the development of gene therapy vectors or drugs targeting these integrins.
Authors with CRIS profile
Involved external institutions
United Kingdom (GB)How to cite
APA:
Schneider, H., Harbottle, R.P., Yokosaki, Y., Kunde, J., Sheppard, D., & Coutelle, C. (1998). A novel peptide, PLAEIDGIELTY, for the targeting of α9β1-integrins. Febs Letters, 429(3), 269-273. https://doi.org/10.1016/S0014-5793(98)00612-7
MLA:
Schneider, Holm, et al. "A novel peptide, PLAEIDGIELTY, for the targeting of α9β1-integrins." Febs Letters 429.3 (1998): 269-273.
BibTeX: Download